Where is Incyte located?

Incyte is headquartered in Frederiksberg, Denmark.

Where does Incyte rank among its competitors?

Incyte ranks 1919th amongst 2090 active competitors, of which 114 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Incyte?

Incyte's top competitors include AbbVie, Merck and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Incyte - 2026 Company Profile & Competitors

Incyte is an unfunded company based in Frederiksberg (Denmark), founded in 2002. It operates as a Developer of therapeutic medicines for patients with unmet medical needs. Incyte has not raised any funding yet. The company has 2090 active competitors, including 114 funded and 219 that have exited. Its top competitors include companies like AbbVie, Merck and Gilead.

Company Details

Developer of therapeutic medicines for patients with unmet medical needs. Research activities involve the discovery, development, and commercialization of pharmaceutical products intended to address serious health conditions. The organization focuses on scientific advancement to provide treatment options for various diseases.

Key Metrics

Founded Year

2002

Location

Frederiksberg, Denmark

Stage

Unfunded

Ranked

1919^th among 2090 active competitors

Similar Companies

AbbVie & 2119 more

View Incyte's full profile

Incyte has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Incyte include AbbVie, Merck and Gilead. Here is the list of Top 10 competitors of Incyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 10 others	84/100
2nd	Merck 1891, Rahway (United States), Public	Manufacturer of pharmaceutical products	-	Bill & Melinda Gates Foundation, Berkshire Hathaway ... & 11 others	83/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	BB Biotech, Jindal Ventures & 18 others	82/100
4th	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	80/100
5th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	77/100
6th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	76/100
7th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 17 others	76/100
8th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	72/100
9th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 12 others	71/100
1919th	Incyte 2002, Frederiksberg (Denmark), Unfunded	Developer of therapeutic medicines for patients with unmet medical needs	-	-	16/100